Navigation Links
Bunge Reports Fourth Quarter Net Income of $245 Million
Date:2/7/2008

859 4,515

Long-term debt 3,435 2,874

Deferred income taxes 149 180

Other non-current liabilities 876 700

Minority interest in subsidiaries 752 410

Shareholders' equity 7,945 5,668

Total liabilities and shareholders' equity $22,016 $14,347

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In millions)

(Unaudited)

Year Ended

December 31,

2007 2006

OPERATING ACTIVITIES

Net income $778 $521

Adjustments to reconcile net income to cash

used for operating activities:

Foreign exchange gain on debt (285) (175)

Impairment of assets 70 20

Bad debt expense 48 41

Depreciation, depletion and amortization 385 324

Stock-based compensation expense 48 19

Deferred income taxes (62) (191)

Gain on sale of assets (22) (36)

(Increase) decrease in the allowance for

recoverable taxes (47) 5

Minority interest 146 60

Equity in earnings of affiliates (33) (23)

Changes in operating assets and liabilities,

excluding the effects of acquisitions:

Trade accounts receivable (319) (69)

Inventories
'/>"/>

SOURCE Bunge Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related biology technology :

1. Digirad Corporation Reports Financial Results for 2007 Fourth Quarter and Twelve Months
2. ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year
3. Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies
4. Recent Research Reports and Near-Term Corporate Events
5. Tutogen Medical, Inc. Reports First Quarter Fiscal 2008 Financial Results
6. Thermo Fisher Scientific Reports Record 2007 Fourth Quarter Revenues and Operating Performance; Provides Guidance for 2008
7. Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History
8. Rochester Medical Reports 31% Increase in Branded Sales Resulting in 9% Overall Sales Growth for the First Quarter
9. Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year
10. CuraGen Reports Fourth Quarter and Year End 2007 Financial Results
11. Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20%
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... PA & Boston, MA (PRWEB) July 28, 2014 ... collaboration agreements with two researchers to further develop potential ... deadly malignant brain tumor, in combination with their patented ... by ITI and Duke University, are based on the ... Chief, Division of Neurosurgery at The Preston Robert Tisch ...
(Date:7/28/2014)... July 28, 2014   Propeller Health , the ... the hire of Brad Towle as Senior ... responsible for driving the company,s sales growth, customer acquisition ... healthcare, and specifically his past role in the development ... company at this pivotal time in the industry," said ...
(Date:7/28/2014)... Appistry, Inc. , a leading ... power of genomics to next-generation medicine, announced today its ... . , Two Appistry staff will be joined ... for Genome Resources, and Mr. Neil Miller, director of ... City. Rounding out the panel are Appistry’s Dr. Richard ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 It’s a hard ... Bill benefits to further their post-secondary education are failing to ... study released this year. And according to an analysis by ... shortfall is veteran students’ uninformed choice of college majors, which ... details of the study: Some 51.7 percent of post-9/11 veterans ...
Breaking Biology Technology:String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 4Propeller Health Hires Brad Towle as Senior Vice President of Business and Client Development 2Appistry Names Industry Experts from the National Center for Genome Resources and Mercy Children's, Kansas City, to Judge Pipeline Challenge Competition 2Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 2Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 3Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 4
... 2008 Lentigen Corporation today,announced an exclusive ... for licensing technologies from the University of,Cambridge ... area of lentiviral vector,technology. The technology was ... at the University of Cambridge., "The ...
... Vice President of Finance -, HOPKINTON, Mass., April ... ) today announced the promotion of Peter F.,McAree to ... as Vice President of Finance at Caliper. Effective April,4, ... CFO., McAree has more than 20 years of ...
... Chairman and CEO Honors the Anniversary by Ringing The Closing Bell(R) ... ... Calif., April 3, 2008 Edwards,Lifesciences Corporation (NYSE: EW ), ... today announced its,50th anniversary of partnering with clinicians to develop life-saving,innovations. ...
Cached Biology Technology:Lentigen Licenses Fundamental Lentiviral Vector Technology Patent From the University of Cambridge 2Lentigen Licenses Fundamental Lentiviral Vector Technology Patent From the University of Cambridge 3Caliper Life Sciences Appoints Peter F. McAree Senior Vice President and Chief Financial Officer 2Edwards Lifesciences Celebrates 50 Years of Life-Saving Innovations 2Edwards Lifesciences Celebrates 50 Years of Life-Saving Innovations 3
(Date:7/25/2014)... factor characterized by the existence of numerous isoforms ... to the protein deeply different characteristics. NRG1 plays ... during development and the different phases occurring after ... regrowth, remyelination and target reinnervation, Researchers at the ... soluble NRG1 upregulation observed in Schwann cells immediately ...
(Date:7/25/2014)... PITTSBURGH -- The routine use of a molecular ... likelihood of performing the correct initial surgery for ... from the University of Pittsburgh Cancer Institute (UPCI), ... the UPMC/UPCI Multidisciplinary Thyroid Center and other diagnostic ... the correct initial surgery by 30 percent, according ...
(Date:7/24/2014)... Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the publication ... 3 study of Zerenex (ferric citrate), the Company,s investigational ... hyperphosphatemia in patients with end-stage renal disease (ESRD) on ... with FErric CiTrate in EsrD) was published online today ... Nephrology ( JASN ). , This ...
Breaking Biology News(10 mins):Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4
... DALLAS May 20, 2008 Mutations in two ... the brain involved in sleep create a human-like insomnia ... found. The findings may help scientists better understand the ... This is one of the most dramatic ...
... exposure to chemicals is on the increase. From food ... with potentially-toxic substances could be affecting our health ... Nottingham are set to take part in one of ... on female mammals. Part of the Reproductive Effects of ...
... CITY Researchers have been unable to build an ... dream of ultrafast optical computers. But now, University of ... photonic crystals with the ideal, diamond-like structure: They are ... beetle from Brazil. It appears that a simple ...
Cached Biology News:Gene mutations in mice mimic human-like sleep disorder, UT Southwestern researchers find 2Do chemicals in the environment affect fertility? 2The photonic beetle 2The photonic beetle 3The photonic beetle 4The photonic beetle 5
... Rabbit polyclonal antibody to human XAB2 ... was first identified through its interaction with ... a fraction of XAB2 interacts with the ... well as with RNA polymerase II. Microinjection ...
... provide custom microplate coating using advanced automated high throughput microplate ... formats. We can also accommodate virtually any lot size of ... , 8 and 12 ... 384 well microplate, ...
...
Mynox is intended for research use only. Mynox is used for the elimination of Mycoplasma and Acholeplasma in cell and virus cultures, and other biologicals....
Biology Products: